ISFIYA, Israel, Nov. 27, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.
Check Cup Propose Business Combination Agreement
Check-Cap has scheduled an Annual General Meeting of Shareholders (the "Meeting") to be held on Monday, December 18, 2023 at 2:00 p.m. (Israel time) at the offices of Check-Cap's Israeli legal counsel, FISCHER (FBC & Co.), located at 146 Menachem Begin Rd., Tel Aviv 6492103, Israel. At the Meeting, investors will be asked to consider and vote on several proposals, including a proposal to approve the Business Combination Agreement. Only shareholders of record at the close of business on November 10, 2023, are entitled to notice of and to vote at the Meeting or at any adjournment thereof.
Keystone Dental Recent Business Development
Financial Results for the Third Quarter Ended September 30, 2023
In anticipation of the initiation of the strategic development plan, management terminated the majority of the Company's research and development activities. As a result, investment in research and development activities and in clinical trials was reduced to $30,000 for the three months ended September 30, 2023, compared to $3.6 million for the same period in 2022. The decrease is primarily comprised of (i) a decrease of approximately $1.8 million in salary and related expenses and a decrease of $0.4 million in share-based compensation resulting from termination of employees (ii) a decrease of $0.8 million in materials and subcontractors and , (iii) a decrease of approximately $0.5 million in other research and development expenses, including clinical related expenses and regulatory consultants.
General and administrative expenses were $2.8 million for the three months ended September 30, 2023, compared to $1.4 million for the same period in 2022. The increase is primarily due to a $1.8 million increase in professional services mainly related to legal and advisors' expenses related to the pending transaction with Keystone Dental and strategic activities, offset in part by a $0.1 million reduction in share-based compensation and a $0.3 million decrease in other general expenses.
Impairment of fixed assets was $60,000 for the three months ended September 30, 2023, compared to none for the same period in 2022. The impairment is associated with the reduction in the Company's operating activities.
Operating loss was $2.9 million for the three months ended September 30, 2023, compared to $5.0 million for the same period in 2022.
Net finance income was $0.3 million for the three months ended September 30, 2023, same as in the comparable period in 2022.
Net loss was $2.6 million for the three months ended September 30, 2023, compared to $4.7 million for the same period in 2022.
Cash and cash equivalents, restricted cash and short-term bank deposits as of September 30, 2023 were $28.2 million, compared with $32.4 million as of June 30, 2023 and $42.1 million as of December 31, 2022.
Financial Results for the Nine Months Ended September 30, 2023
In anticipation of the initiation of the strategic development plan, management terminated the majority of the Company's research and development activities. As a result, investment in research and development activities and in clinical trials was reduced to $8.2 million for the nine months ended September 30, 2023, compared to $11.3 million for the same period in 2022. The decrease is primarily comprised of (i) a decrease of approximately $1.9 million in salary and related expenses and $0.5 million decrease in share-based compensation as a result of termination of employees (iii) a decrease of approximately $0.7 million in materials and subcontractors and other research and development expenses, including clinical related expenses and regulatory consultants, mainly associated with the termination of clinical studies and operations.
General and administrative expenses were $5.6 million for the nine months ended September 30, 2023, compared to $4.5 million for the same period in 2022. The increase is primarily due to a $1.9 million increase in professional services mainly related to legal and advisors' expenses relating to the pending transaction with Keystone Dental and strategic activities, and $0.1 million in salary and related expenses including directors' fees, offset in part by a $0.3 million reduction in share-based compensation and a $0.6 million decrease in other general expenses, mainly associated with directors' and officers' liability insurance costs.
Impairment of fixed assets was $1.4 million for the nine months ended September 30, 2023. Due to the changes in circumstances that indicate that the carrying amount of an asset may not be recoverable, the Company reviewed its long-lived assets for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets". Therefore, the Company recorded an impairment loss of $1.4 million.
Operating loss was $15.2 million for the nine months ended September 30, 2023, compared to $15.8 million for the same period in 2022.
Net finance income was $1.3 million for the nine months ended September 30, 2023, compared to $0.4 million for the same period in 2022. The increase in finance income, net is primarily due to an increase in interest income on short-term deposits of $0.8 million.
Net loss was $13.9 million for the nine months ended September 30, 2023, compared to $15.4 million for the same period in 2022.
Net cash used in operating activities was $13.4 million for the nine months ended September 30, 2023, compared to $14.6 million for the same period in 2022.
About Keystone Dental Group:
Keystone Dental is a global commercial-stage medical technology company focused on providing end-to-end tooth replacement solutions for dental practitioners. Headquartered in Irvine, California, and with research and development and manufacturing sites in Caesarea, Israel and Melbourne, Australia, Keystone Dental markets its products worldwide. The Company's product portfolio includes proprietary offerings such as its innovative implant systems Genesis Active, Molaris™ and Prima Plus™ that offer unique solutions to dental practitioners. In addition, the Company also offers an attractive dental implant value brand in Paltop, and a well-regarded portfolio of biomaterials mainly sold under the DYNA brand. Keystone Dental acquired Implant Solutions Pty Ltd ("Osteon") in 2021, adding a comprehensive portfolio of prosthetic solutions on implants and digital workflow capabilities, not least of which is the groundbreaking Nexus iOS digital workflow solution for restoring the fully edentulous patient. For more information, refer to www.keystonedental.com.
About Check-Cap
Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, a screening test designed to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. C-Scan is an investigational device and is not available for sale in the United States.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Participants in the Solicitation
Check-Cap, Keystone Parent and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies from the shareholders of Check-Cap in connection with the business combination. Information about Check-Cap's directors and executive officers is set forth in Check-Cap's Annual Report on Form 20-F for the year ended December 31, 2022 which was filed with the SEC on March 31, 2023. Information about Keystone Dental's directors and executive officers will be set forth in the prospectus (when available). Other information regarding the interests of such individuals, as well as information regarding other persons who may be deemed participants in the business combination, will be set forth in the prospectus, the proxy statement and other relevant materials to be filed or submitted with the SEC when they become available. Investors, Keystone security holders and Check-Cap security holders and other readers should read the prospectus and the proxy statement carefully when they become available before making any voting or investment decisions.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
Investor contacts:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
This email address is being protected from spambots. You need JavaScript enabled to view it.
Meirav Gomeh-Bauer
LifeSci Advisors, LLC
+972(0)-54-476-4979
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact:
Mónica Rouco Molina, Ph.D.
Account Supervisor - Europe
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
CHECK CAP LTD
CONSOLIDATED UNAUDITED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
Unaudited | Audited | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 3,383 | $ | 4,090 | ||||
Restricted cash | 130 | 352 | ||||||
Short-term bank deposit | 24,684 | 37,609 | ||||||
Prepaid expenses and other current assets | 577 | 579 | ||||||
Total current assets | 28,774 | 42,630 | ||||||
Non-current assets | ||||||||
Property and equipment, net | 183 | 1,751 | ||||||
Operating leases | 73 | 1,060 | ||||||
Total non-current assets | 256 | 2,811 | ||||||
Total assets | $ | 29,030 | $ | 45,441 | ||||
Liabilities and shareholders' equity | ||||||||
Current liabilities | ||||||||
Accounts payable and accruals | ||||||||
Trade | $ | 108 | $ | 952 | ||||
Other | 717 | 802 | ||||||
Employees and payroll accruals | 757 | 1,261 | ||||||
Other current liabilities | 23 | 56 | ||||||
Operating lease liabilities | 30 | 337 | ||||||
Total current liabilities | 1,635 | 3,408 | ||||||
Non-current liabilities | ||||||||
Royalties provision | - | 94 | ||||||
Operating lease liabilities | - | 627 | ||||||
Total non-current liabilities | - | 721 | ||||||
Shareholders' equity | ||||||||
Share capital, Ordinary shares, 48 NIS par value (18,000,000 authorized shares as of | ||||||||
31, 2022, respectively; 5,850,100 and 5,844,463 shares issued and outstanding as of September | 83,740 | 83,664 | ||||||
Additional paid-in capital | 84,858 | 84,941 | ||||||
Accumulated deficit | (141,203) | (127,293) | ||||||
Total shareholders' equity | 27,395 | 41,312 | ||||||
Total liabilities and shareholders' equity | $ | 29,030 | $ | 45,441 | ||||
CHECK CAP LTD
CONSOLIDATED UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS
(U.S. dollars in thousands, except share and per share data)
Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Research and development expenses, net | $ | 8,181 | $ | 11,315 | $ | 30 | $ | 3,641 | ||||||||
General and administrative expenses | 5,595 | 4,504 | 2,833 | 1,404 | ||||||||||||
Impairment of fixed assets | 1,426 | - | 62 | - | ||||||||||||
Operating loss | 15,202 | 15,819 | 2,925 | 5,045 | ||||||||||||
Finance Income , net | 1,292 | 424 | 335 | 291 | ||||||||||||
Loss before income tax | 13,910 | 15,395 | 2,590 | 4,754 | ||||||||||||
Net loss for the period | $ | 13,910 | $ | 15,395 | $ | 2,590 | $ | 4,754 | ||||||||
Loss per share: | ||||||||||||||||
Net loss per ordinary share basic and diluted | $ | 2.38 | $ | 2.74 | $ | 0.44 | $ | 0.81 | ||||||||
Weighted average number of ordinary shares outstanding - basic and diluted | 5,849,189 | 5,613,696 | 5,849,756 | 5,842,205 | ||||||||||||
CHECK CAP LTD.
CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(U.S. dollars in thousands, except share and per share data)
Number of | Additional | Total | |||||||||||||||
Ordinary | paid-in | Accumulated | shareholders' | ||||||||||||||
Shares | Amount | capital | deficit | equity | |||||||||||||
Balance as of January 1, 2023 | 5,844,463 | $ | 83,664 | $ | 84,941 | $ | (127,293) | $ | 41,312 | ||||||||
RSUs vesting | 5,637 | 76 | (76) | - | - | ||||||||||||
Share-based compensation | - | - | (7) | - | (7) | ||||||||||||
Net loss | - | - | - | (13,910) | (13,910) | ||||||||||||
Balance as of September 30, 2023 | 5,850,100 | $ | 83,740 | $ | 84,858 | $ | (141,203) | $ | 27,395 | ||||||||
Balance as of January 1, 2022 | 4,840,089 | $ | 68,787 | $ |
90,089 | $ | (108,185) | $ | 50,691 | ||||||||||
Issuance of ordinary | 1,000,000 | 14,815 | (5,965) | - | 8,850 | ||||||||||||||
RSUs vesting | 3,564 | 51 | (51) | - | - | ||||||||||||||
Share-based compensation | - | - | 779 | - | 779 | ||||||||||||||
Net loss | - | - | - | (15,395) | (15,395) | ||||||||||||||
Balance as of September 30, 2022 | 5,843,653 | $ | 83,653 | $ | 84,852 | $ | (123,580) | $ | 44,925 | ||||||||||
CHECK CAP LTD.
CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(U.S. dollars in thousands, except share and per share data)
Number of | Additional | Total | ||||||||||||
Ordinary | paid-in | Accumulated | shareholders' | |||||||||||
Shares | Amount | capital | deficit | equity | ||||||||||
Balance as of June 30, 2023 | 5,849,216 | $ | 83,728 | $ | 85,075 | $ | (138,613) | $ | 30,190 | |||||
RSU's vesting | 884 | $ | 12 | (12) | - | |||||||||
Share-based compensation | - | - | $ | (205) | $ | (205) | ||||||||
Net loss | - | - | - | $ | (2,590) | $ | (2,590) | |||||||
Balance as of September 30, 2023 | 5,850,100 | $ | 83,740 | $ | 84,858 | $ | (141,203) | $ | 27,395 | |||||
Balance as of June 30, 2022 | 5,840,089 | $ | 83,602 | $ | 84,648 | $ | (118,826) | $ | 49,424 | |||||
RSU's vesting | 3,564 | $ | 51 | $ | (51) | - | - | |||||||
Share-based compensation | - | - | $ | 255 | - | $ | 255 | |||||||
Net loss | - | - | - | $ | (4,754) | (4,754) | ||||||||
Balance as of September 30, 2022 | 5,843,653 | $ | 83,653 | $ | 84,852 | $ | (123,580) | $ | 44,925 | |||||
CHECK-CAP LTD.
CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands, except share and per share data)
Nine months ended | ||||||||
September 30, | ||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (13,910) | $ | (15,395) | ||||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 190 | 254 | ||||||
Impairment of fixed assets | 1,426 | - | ||||||
Share-based compensation | (7) | 779 | ||||||
Financial income, net | 374 | (295) | ||||||
Changes in assets and liabilities items: | ||||||||
Decrease in prepaid and other current assets and non-current assets | 37 | 248 | ||||||
(Decrease) Increase in trade accounts payable, accruals and other current liabilities | (926) | 6 | ||||||
Decrease in employees and payroll accruals | (505) | (127) | ||||||
Decrease in royalties provision | (94) | (30) | ||||||
Net cash used in operating activities | $ | (13,415) | $ | (14,560) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (83) | (395) | ||||||
Investment in short-term bank and other deposits | 12,569 | (11,000) | ||||||
Net cash used in investing activities | $ | 12,486 | $ | (11,395) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Issuance of ordinary shares in the registered direct offerings, net of issuance expenses | - | 8,850 | ||||||
Net cash provided by financing activities | $ | - | $ | 8,850 | ||||
Net decrease in cash, cash equivalents and restricted cash | (929) | (17,105) | ||||||
Cash, cash equivalents and restricted cash at the beginning of the period | 4,442 | 26,807 | ||||||
Cash, cash equivalents and restricted cash at the end of the period | $ | 3,513 | $ | 9,702 | ||||
Nine months ended September 30, | ||||||||
2023 | 2022 | |||||||
Supplemental disclosure of non-cash flow information | ||||||||
Purchase of property and equipment included in accounts payable and accrued expenses | - | 89 | ||||||
Assets acquired under operating lease | 136 | 307 | ||||||
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for taxes | 2 | 23 | ||||||
Interest received | 1,720 | 377 | ||||||
| Last Trade: | US$2.29 |
| Daily Change: | 0.02 0.66 |
| Daily Volume: | 22,710 |
| Market Cap: | US$13.370M |
November 28, 2023 November 13, 2023 November 06, 2023 August 16, 2023 August 04, 2023 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
